Kornimate/medical-research-clean huggingface dataset:
algorithm of muscle function tests to detect residual neuromuscular blockade.

Conditions: Postoperative Residual Curarization

Summary: objective neuromuscular monitoring is the gold standard to detect postoperative residual curarization (porc). many anesthesiologist just use qualitative neuromuscular monitoring or unreliable, clinical tests. goal of this study is to develop an algorithm of muscle function tests to identify porc

background: quantitative neuromuscular monitoring is the gold standard to detect postoperative residual curarization (porc). many anesthesiologists, however, use insensitive, qualitative neuromuscular monitoring or unreliable, clinical tests. goal of this multicentre, prospective, double-blinded, assessor controlled study is to develop an algorithm of muscle function tests to identify porc. methods: after extubation a blinded anesthetist performs eight clinical tests in 165 patients. test results are correlated to calibrated electromyography train-of-four (tof) ratio and to a postoperatively applied uncalibrated acceleromyography. a classification and regression tree (cart) is calculated developing the algorithm to identify porc. this is validated against uncalibrated acceleromyography and tactile judgement of tof fading in separate 100 patients.

Eligibility criteria:
inclusion criteria: the patients were scheduled for elective low risk surgical procedures: * laparoscopic abdominal procedures * orthopedic * minor visceral surgery exclusion criteria: * participation in another study * body mass index over 30 * history of neuromuscular diseases * gastro-esophageal reflux disease.

Keywords: muscle function tests
epiceram™ device versus mid-strength topical steroid (fluticasone propionate 0.05%) for treatment of atopic dermatitis

Conditions: Atopic Dermatitis

Summary: novel therapies for ad that avoid immunosuppression and potential carcinogensis are needed. epiceram™ , a topical cream, represents a novel class of therapy for skin disorders that does not contain corticosteroids or other anti-inflammatory drugs. the objective of the present study is to demonstrate the safety and efficacy of epiceram ™ in the treatment of moderate to severe atopic dermatitis as compared to mid-strength topical steroid cream following twice daily dosing for four weeks in pediatric patients with ad. the potential benefit to patients lies in the potential for epiceram ™ to provide restoration of the normal skin barrier as shown in previous studies and eliminate or reduce the requirement for supplemental topical steroid administration.


Eligibility criteria:
inclusion criteria: * subjects willing to provide written informed consent (i.e. assent with parental/guardian consent for ages \> 7 to 18 years and parental consent for ages 6 months to 7 years) to participate in the study * males or females * age: 6 months to 18 years * diagnosis of moderate to severe atopic dermatitis (ad) on the basis of criteria defined by the rajka-langland severity index exclusion criteria: * subjects with mild ad as defined by the rajka-laneland severity index. * subjects having greater than 20% bsa as measured by scorad "extent" (a) score (total amount of body surface area requiring application of either cutivate® or epiceram® exceeds 20%) * subjects with unstable or uncontrolled medical conditions that could require intensive treatment during the course of the study. * subjects who require greater than 2mg per day of inhaled or intranasal steroids. * subjects who are currently participating in, or have participated in another investigational drug/device trial within the past month. * subjects with known allergy to or hypersensitivity to epiceram™ or fluticasone or cetaphil. * active infection of any type at the start of the study.

Keywords: atopic dermatitis eczema skin barrier ceramide topical inflamation steroid scorad glucocorticoids epiceram cutivate fluticasone
diabetes complications and hearing loss

Conditions: Diabetes Mellitus; Diabetes Complications; Hearing Loss

Summary: observation study, shows the relation between diabetes, its neurological and optical complication and hearing loss, by asking participants questions about there age,bmi,job,the history of any cataract,diabetes retinopathy or heart attack,hypertension,swollen or tingling legs and take there consent to measure the hearing impairment.


Eligibility criteria:
inclusion criteria: * diabetics who signed consent for the study. * diabetics who have filled out the form completely. * diabetics who have undergone a pure tone hearing screening test . exclusion criteria: * patients with glandular disease causing hearing loss. * patients with traumatic ear injury. * patients who have recently had a middle or inner ear infection. * history of acoustic neuroma. * patients are under active treatment with medications that have a toxic effect on the auditory cells. * patients with diabetic foot. * the patient's occupation or residence is within a noisy environment.

Keywords: diabetes retinopathy cataract
induction toripalimab and chemotherapy in locally advanced cervical cancer

Conditions: Cervical Cancer; Induction Chemotherapy; Immunotherapy

Summary: to explore the efficacy of incorporating neoadjuvant immunotherapy into neoadjuvant chemotherapy in locally advanced cervical cancer patients with high risk of recurrence.

for locally advanced cervical cancer patients undergoing definitive chemoradiotherapy, distant metastasis has become a major concern. in this study, investigators selected a subgroup of patients with theoretically higher risk of distant metastasis and intensified their systematic treatment by incorporating pd-l1 inhibitors into neoadjuvant chemotherapy, in order to reduce their risk of distant metastasis and achieve good disease-free survival.

Eligibility criteria:
inclusion criteria: 1. untreated locally advanced cervical cancer patients with clear pathological diagnosis 2. 2019 figo stage iiib-iva. for patients with stage iiic disease, the short diameter of their metastatic lymph nodes should ≥1.5cm 3. eastern cooperative oncology group (ecog) performance status 0-1 4. life expectancy \> 6 months 5. able to tolerate concurrent chemoradiotherapy assessed by researches 6. no obvious active bleeding; 7. adequate hematological, renal and hepatic functions: 8. no concomitant malignancies 9. female subjects of childbearing potential should have a negative pregnancy test and must take effective and reliable contraceptive measures during the clinical trial period; 10. voluntarily-signed informed consent. exclusion criteria: 1. concomitant other malignancies; 2. patients with metastatic or recurrent disease; 3. patients received any form of treatment before enrollment; 4. severe concomitant chronic diseases (diabetes, hypertension, etc.) or acute infections; 5. impaired hematological, renal or hepatic functions: 1. hemoglobin \< 9.0 g/dl 2. neutrophils \< 2000 cells/μl; leukocytes \< 4 × 109/l 3. platelets \> 100 × 109/l 4. serum alt/ast \> 2.5×unl 5. serum total bilirubin \> 1.5× unl g. serum urea nitrogen (bun) \> 1.5 × upper normal limit (unl) h. serum creatinine (cr) \> 1.5 × upper normal limit (unl) 6. patients with obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac insufficiency or severe heart valve disease; 7. patients with uncontrolled mental diseases; 8. pregnant or lactating woman; 9. participating in other clinical trials; 10. anyone considered not suitable for enrollment by principal investigator;

Keywords: cervical cancer immunotherapy neoadjuvant chemotherapy chemoradiation
atg versus basiliximab in kidney transplant displaying low immunological risk but high susceptibility to dgf

Conditions: Kidney Transplantation

Summary: the primary objective of the following randomized open label trial is to demonstrate how low immunological risk patients (no anti hla immunization and first kidney transplantation) but diagnosed at high-risk of delayed graft function (assessed by dgfs score) could benefit from induction with atg for preventing delayed graft function compared to basiliximab.


Eligibility criteria:
inclusion criteria: * adults * first kidney transplantation * no anti hla immunization prior transplantation * a risk of dgf higher than 40% calculated by the score dgfs (dgfs \>= 0.4) * written informed consent exclusion criteria: * previous or combined other transplantations * non heart beating donors * living donors * pre-emptive transplantation * patients on peritoneal dialysis * leucopenia lower than 3000/mm3 * thrombopenia lower than 100 000/mm3 * donor ebv positive / recipient ebv negative * pregnant or lactating women * patients under guardianship * previous and current history of cancer and/or lymphoma * current history of hcv or hbv or hiv infection

Keywords: transplantation kidney delayed graft function induction therapy personalized medicine first kidney transplantation no anti hla immunization prior transplantation risk of dgf higher than 40% calculated byt he score dgfs
tenapanor in synucleinopathy-related constipation

Conditions: Synucleinopathy; Parkinson's Disease

Summary: investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation

randomized, double-blind, placebo controlled trial of tenapanor vs. placebo for treating synucleinopathy-associated constipation in parkinson\&#39;s disease.

Eligibility criteria:
inclusion criteria 1. age 50-89 years. 2. diagnosis of pd within hoehn and yahr stages 1-3, confirmed by a neurologist per international parkinson and movement disorder society criteria. 3. average weekly stool frequency of ≤5 spontaneous bowel movements (sbms) and ≤2 complete spontaneous bowel movements (csbms) over the past 6 months. these criteria will be verified during a 2-week screening period. 4. stool consistency ≤3 on the bristol stool form scale (bsfs). this criterion will be verified during a 2-week screening period. 5. agreement to use contraception, if applicable. exclusion criteria 1. functional diarrhea or ibs-d/m based on rome iv criteria. 2. symptomatic structural gi abnormalities or inflammatory bowel disease. 3. significant hepatic (alt or ast ≥ 2.5x the upper limit of normal) or renal (serum creatinine \>2mg/dl) dysfunction. 4. pregnancy or lactation. 5. diagnosis of primary dyssynergic defecation by anorectal manometry.

Keywords: tenapanor synucleinopathy parkinson's disease constipation
safety and efficacy study of regulatory t cells in treating autoimmune hepatitis

Conditions: Autoimmune Diseases

Summary: separated and expanded the cd4+cd25+cd127- tregs from peripheral blood of autoimmune hepatitis patients and administrate the cells (5 x 106 cells/kg) into patients.

the trial will be carried out in autoimmune patients. the investigators will isolate cd4(cluster of differentiation)+cd25(cluster of differentiation25)+cd127(cluster of differentiation127)- tregs from these patients, and expand them with il(interleukin)-2 retinoid acid and anti-cd3(cluster of differentiation 3) /cd28(cluster of differentiation 28) beads. the patients will be subsequently treated with single infusion of cd4+cd25+cd127- tregs (10-20 x 106 cells/kg). in the clinical trials, the investigators will monitor the number of tregs in patients at different periods, and to test their suppressive functions in vitro. also the function and biopsy of liver will be processed to determine the efficacy of treg therapy.

Eligibility criteria:
inclusion criteria: 1. written informed consent 2. autoimmune hepatitis(according to the criteria defined by the international autoimmune hepatitis group ,hepatology, 2008;48:169-176) 3. negative pregnancy test 4. moderately active disease under standard treatment exclusion criteria: 1. hepatocellular carcinoma or other malignancies 2. pregnant or lactating women 3. vital organs failure (cardiac, renal or respiratory, et al) 4. sepsis 5. active thrombosis in the portal or hepatic veins 6. concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent 7. surgery during the last 2 months or surgery planned during the study, 8. participation in other biomedical research in the last 3 months or planned during the study.

Keywords: autoimmune diseases, treg
thyroid cancer database

Conditions: Patients With a Thyroid Tumor Who Received Radioactive Iodine Treatment

Summary: thyroid cancer database collects clinical and laboratory data from patients with a thyroid tumor who received radioactive iodine treatment. this database only records information based on patients' medical files in a structured manner. thyroid database is used for retrospective non-interventional research projects.


Eligibility criteria:
inclusion criteria: * patients with a thyroid tumor (metastatic or not) * patients who received radioactive iodine treatment. * age \>= 18 exclusion criteria: * objection to collect medical data records

Keywords: thyroid cancer, iodine treatment
effect of meal composition on postprandial testosterone concentration in women with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: the primary objective is to determine if meals of different fat and fiber content affect postprandial plasma testosterone concentration in women with polycystic ovary syndrome. our hypothesis is that a high-fiber meal will have a greater reduction in testosterone composition compared with a high-fat meal.

the study participants are 15 women with pcos between the ages of 19-40. all participants must be in good health, non-smokers, and not pregnant or lactating. for three days prior to both study visits, participants follow a standard 2,000 calorie meal plan of approximately 30% fat, 55% carbohydrate and 15% protein. on the morning of the two study visits, participants arrive at the general clinical research center at 0700 h. a venicatheter is inserted into an antecubital vein for collection of blood samples and the catheter is kept open with saline. a baseline blood sample is taken for measurement of estradiol, progesterone, glucose, insulin, testosterone, and sex hormone binding globulin (shbg). participants are then served the test meal and asked to consume it within 15 minutes. the high-fat, low-fiber and low-fat, high-fiber meals are isocaloric and are 62% and 6% fat, 24% and 81% carbohydrate, and have 1g and 26.8g of fiber, respectively. after each meal, a blood sample is taken at 30 minutes and every hour for six hours for measurement of testosterone, shbg, glucose and insulin. during this time participants remain comfortably seated or reclined. after the last blood draw, the catheter was removed and participants are given a complementary meal.

Eligibility criteria:
inclusion criteria: * chronic oligo/anovulation - intermenstrual periods of ≥ 45 days or ≤ 8 menses per year. * hyperandrogenemia - elevated total testosterone or free androgen index (ratio of testosterone/shbg x 100). to participate in the study, women must have total testosterone \>50 ng/dl or a free androgen index \>1.5 * in good general health exclusion criteria: * currently pregnant or lactating * use of confounding medications such as oral contraceptives or other hormonal medication, lipid lowering medications or insulin sensitizing agents such as metformin or the glitazones. * tobacco use * alcohol consumption of more than two drinks per day * unusual meal patterns (including no breakfast, breakfast before 6 am or breakfast after 10am. * untreated hyperprolactinaemia (prolactin \>25ng/ml) * uncontrolled hypothyroidism * history of blood clotting disorder * diagnosis of anemia at baseline visit * presence or history of diabetes mellitus * existence of an organic intra cranial lesion such as a pituitary tumor. * presence or history of coronary artery disease

Keywords: meal composition postprandial pcos androgen
investigation of inflammation in alzheimer's disease and related dementias (adrd) using [11c]-cs1p1

Conditions: Alzheimer Disease

Summary: this study involves a brain positron emission tomography (pet) scan with a new, investigational radioactive tracer called \[11c\]-cs1p1 to identify inflammation in the brain by testing with healthy older adults and with cognitively impaired older adults.

the primary objective of this ind study is to further evaluate the \[11c\]-cs1p1 for pet imaging of s1p1 expression in healthy older adults and in adults with alzheimer's disease and related dementia (adrd). investigators will complete imaging of the brain and neck in older adults with normal cognition and those with clinically diagnosed cognitive impairment from adrd to characterize \[11c\]-cs1p1 uptake in the brain. investigators will compare the normal cognition participants to patients with adrd to collect preliminary data that will subsequently test the hypothesis that \[11c\]-cs1p1 uptake is elevated in patients with adrd.

Eligibility criteria:
inclusion criteria: * male or female, any race; * age ≥ 50 years; * capable of providing written informed consent or having a legally authorized representative (lar) to provide informed consent for volunteering to undergo research procedure; * additional inclusion for adrd group: clinical diagnosis of mild cognitive impairment or early dementia due to adrd, or biomarker diagnosis of alzheimer's disease, with or without symptoms. exclusion criteria: * hypersensitivity to \[11c\]-cs1p1 or any of its excipients; * contraindications to pet, ct, or mri (e.g. certain incompatible electronic medical devices, inability to lie still for extended periods) that make it potentially unsafe for the individual to participate; * severe claustrophobia; * women who are currently pregnant or breast-feeding; * currently undergoing radiation therapy; * any condition that, in the opinion of the sponsor-investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with collection of the data (e.g., renal or liver failure, advanced cancer); * participants who in the last 6 months experienced any of the following cardiovascular conditions or findings in the screening electrocardiogram (ecg): clinically significant cardiac arrhythmias including high grade heart block (type 2 or greater), unstable angina, or decompensated heart failure requiring hospitalization or class iii/iv heart failure; * moderate to severe anemia with hemoglobin \< than 9.9 in both males and females. * current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the u.s. code of federal regulations (cfr) title 21 section 361.1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=361.1
study evaluating etanercept for the treatment of active, severe, and advanced axial ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: evaluation of the efficacy and safety of etanercept (enbrel) in patients with active, severe and advanced ankylosing spondylitis.


Eligibility criteria:
inclusion criteria * active and severe ankylosing spondylitis * ankylosing spondylitis refractory to standard anti-rheumatic treatment * between 18 and 70 years of age exclusion criteria * prior exposure to any tnf-inhibitor, including etanercept * dmards (other than hydroxychloroquine, methotrexate and sulphasalazine) within 4 weeks of study drug initiation * dose of nsaids changed within two weeks of study drug initiation

Keywords: axial ankylosing spondylitis adult
growth factors in the treatment of the multiple gingival recessions

Conditions: Growth Factors, Combined Defect of; Gingival Recession

Summary: the purpose of this study was to compare and evaluate the clinical effects of concentrated growth factor (cgf) and advanced platelet-rich fibrin (a-prf) applied together with coronally advanced flap (caf) technique using a microsurgical approach in the treatment of type i multiple gingival recessions (gr).


Eligibility criteria:
inclusion criteria: * systematically and periodontally healthy non-smokers * presence of cairo recession type i gingival recession with ≥ 2 mm gingival recession depth, probing depth \<3 mm and gingival thickness (gt) ≥ 0.8 mm on both sides of the maxillary arch * width of keratinized gingiva ≥ 2mm * presence of identifiable cemento-enamel junction * full-mouth plaque index (pi) \< 20 % * gingival index (gi) scores =1 * presence of tooth vitality * absence of caries, restorations and furcation involvement in the treated area exclusion criteria: * patients who had systemic problems that wound contraindicate for periodontal surgery * usage of medications known to interfere with healing and to cause gingival enlargement * recession defects associated with demineralization, deep abrasion, previous surgery in the defects area within the past 1 year * pregnant or lactating females * drug and alcohol abuse
vascular endothelial growth factor (vegf) in uveitis

Conditions: Macular Edema, Cystoid; Uveitis

Summary: this study will look for the presence in blood of a substance called vascular endothelial growth factor (vegf) in patients with uveitis (eye inflammation). it will also look for this substance in eye fluid samples taken from patients with uveitis who are undergoing eye surgery. some patients with uveitis experience some vision loss during an inflammatory attack because of swelling (edema) in a particular area of the retina called the macula, which is involved in visual acuity. it may be that vegf is involved in the development of macular edema. patients with uveitis who participate in this study will have about 10 cc (2 teaspoons) of blood drawn to be examined for vegf. they will also undergo a procedure called fluorescein angiography to look at the blood vessels of the eye. a dye called sodium fluorescein is injected into the blood stream through a vein. after the dye reaches the blood vessels of the eye, photographs are taken of the retina. in addition, patients with uveitis who are undergoing eye surgery will have a tissue specimen (either aqueous fluid or vitreous gel) collected for examination for the presence of vegf.

increased intraocular and systemic levels of the angiogenic factor vascular endothelial growth factor (vegf) is associated with new vessel growth in the eye, such as diabetic retinopathy. recent work using immunopathologic techniques have shown that vegf is upregulated in both experimentally induced uveitis and in uveitic eyes as well, with no evidence of neovascularization. this pilot study will evaluate the level of vegf in the blood of uveitic patients with and without macular edema. this level will be determined also in the ocular fluid of those patients that are undergoing ocular surgery. these levels will be compared with age and sex matched controls.

Eligibility criteria:
for uveitis patients: evidence on ocular examination in the past or presently of intraocular inflammation, with cells and haze in the vitreous for the intermediate and posterior uveitis patients. in order to demonstrate the presence or absence of macular edema, a fluorescein angiogram will be attempted on all patients. however, if the patient is unable or not willing to undergo the test, then if two observers from the li can substantiate independently that there is or is not evidence of cystoid edema, the patient may be included.

Keywords: intermediate uveitis pars planitis retinal vasculature uveitis vascular permeability vitreous